Alpha 2.0
Login Register
» Authors » K Knobe

K Knobe

Explore the profile of K Knobe including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 139
Followers 0
Related Specialty
Hematology
Top 10 Co-Authors
E Berntorp
S R Lentz
T Matsushita
D Viuff
C Rea
V Jimenez-Yuste
M Recht
J Moss
R Lindahl
E C Rodriguez-Merchan
Published In
Haemophilia
J Thromb Haemost
Affiliations
Soon will be listed here.
Recent Articles
1.
Evaluation of prophylactic therapy in haemophilia with global coagulation tests
Zetterberg E, Brolin K, Lindahl R, Knobe K, Berntorp E
Haemophilia . 2017 Oct; 24(1):e10-e13. PMID: 29063652
No abstract available.
2.
Comparative burden of arthropathy in mild haemophilia: a register-based study in Sweden
Osooli M, Lovdahl S, Carlsson K, Knobe K, Baghaei F, Holmstrom M, et al.
Haemophilia . 2017 Feb; 23(2):e79-e86. PMID: 28155262
Introduction: Mild haemophilia is a congenital bleeding disorder affecting males. The burden of arthropathy in mild haemophilia has not been comprehensively described. Aim: The aim of this study was to...
3.
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
Mahlangu J, Weldingh K, Lentz S, Kaicker S, Karim F, Matsushita T, et al.
J Thromb Haemost . 2015 Sep; 13(11):1989-98. PMID: 26362483
Background: Vatreptacog alfa, a recombinant human factor VIIa (rFVIIa) analog developed to improve the treatment of bleeds in hemophilia patients with inhibitors, differs from native FVIIa by three amino acid...
4.
Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A
Tiede A, Brand B, Fischer R, Kavakli K, Lentz S, Matsushita T, et al.
J Thromb Haemost . 2013 Feb; 11(4):670-8. PMID: 23398640
Background: N8-GP is a recombinant factor VIII (FVIII) with a site-directed glycoPEGylation for the purpose of half-life prolongation. Objectives: To evaluate the safety and pharmacokinetic profiles of N8-GP in comparison...
5.
Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX
Collins P, Moss J, Knobe K, Groth A, Colberg T, Watson E
J Thromb Haemost . 2012 Sep; 10(11):2305-12. PMID: 22998153
Background: nonacog beta pegol (N9-GP) is a glycoPEGylated recombinant factor IX (rFIX) molecule with a prolonged half-life. Objectives: To provide information on potential dose regimens for N9-GP for phase 3...
6.
Joint protection in haemophilia
Rodriguez-Merchan E, Jimenez-Yuste V, Aznar J, Hedner U, Knobe K, Lee C, et al.
Haemophilia . 2011 Aug; 17 Suppl 2:1-23. PMID: 21819491
Haemarthroses (intra-articular haemorrhages) are a frequent finding typically observed in patients with haemophilia. Diagnosis and treatment of these bleeding episodes must be delivered as early as possible. Additionally, treatment should...